Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention

Study Overview
=================
Brief Summary
-----------------
In stent restenosis and myocardial infarction are have been linked the balance between injury and healing of the endothelium These processes can be measured respectively using the number of circulating endothelial cells and endothelial progenitor cells. We therefore aimed to evaluate the relationship between the balance of injury and healing of the endothelium at the time of PCI and major adverse cardiovascular events including death, myocardial infarction and target lesion revascularization at 6 and 12 months follow-up.

Detailed Description
-----------------
Following percutaneous coronary intervention with bare metal stents, the rate of major adverse cardiovascular events including death, myocardial infarction and target lesion revascularization is high ranging between 20 and 25%.

Official Title
-----------------
Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention.

Conditions
-----------------
Atherosclerosis, Percutaneous Coronary Intervention, Cardiovascular Diseases

Intervention / Treatment
-----------------
* Other: Data private hospitals, angioplasty, sampling of blood


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age>18 years old Scheduled for PCI Clinical evidence of ischemic heart disease and/or abnormal functional study New coronary artery lesion >50% treatment with bare metal stent planned Informed consent explained, red, understood and signed by the patient Exclusion Criteria: Pregnancy, birth or lactation period <6 months ago Women of childbearing age who do not intend to use accepted anticonceptive measures or who wish to get pregnant Left ventricular ejection fraction <30% Acute coronary syndrome (ST-elevation or not) in the past month Planned drug eluting stent implantation Lesion in arterial or venous bypass or anastomosis with coronary Severe renal insufficiency (creatinine clearance <30 mL/') Severe hepatic insufficiency Systemic inflammatory pathology of any kind Hematologic or other malignancy, prior radio- or chemotherapy Use of corticosteroïds or immune suppression therapy Contrast allergy Life expectancy <1 year Participation in other clinical study which has not ended yet

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>Data private hospitals, angioplasty, sampling of blood | Other: Data private hospitals, angioplasty, sampling of blood<br>* Data private hospitals : Age, sex, index of body mass, factors of cardiovascular risk, medical surgical histories, treatment before and after the angioplasty, the renal insufficiency coronary angioplasty Sampling of blood : Before the angioplasty, 6 hours after the angioplasty and 24 hours after the angioplasty. A numeration of the proparents circulants (hématopoietics, PEC) and a numeration of CEC are made<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The main objective of this study is to estimate if the measure of CEC and PEC possesses a meaning forecast towards the arisen of complications post procedure. |  | 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the relation between these endothelial biomarkers and the other usual parameters forecast complications post-angioplasty |  | 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Major adverse